In Law360 and Managed Healthcare Executive, Margaux Hall Discusses Government Process on First 10 Drugs Selected for Medicare Price Negotiation

In The News
August 30, 2023

In Law360 and Managed Healthcare Executive article, health care partner Margaux Hall, who leads the firm’s drug pricing and price reporting group, discussed the Centers for Medicare & Medicaid Services release of the list including the first 10 drugs to be negotiated under the Inflation Reduction Act. The legislation allows CMS to negotiate certain Medicare drug prices.

Margaux expects further scrutiny of CMS’s authority to negotiate drug prices, as well as potential litigation and market ramifications. “It is possible that litigants in existing lawsuits may respond to the publication of the drug listing and seek further legal redress. Across the broader pharmaceutical industry, I expect to see lots of dissection of this list to try to reverse engineer the agency’s criteria and processes for selection. I also expect follow-on analysis about implications for drugs that may be selected in later years,” said Margaux.